Stantec, the engineering company, has experienced a significant boost in its shares following a stronger-than-expected third-quarter earnings report. This increase in earnings is largely attributed to continued robust demand, particularly in the U.S. and Canada.
In Toronto, the shares surged by 7.6% to reach C$93.84, bringing the year-to-date advance to an impressive 45%. On the New York Stock Exchange, the stock also saw a significant uptick of 7.5% to $67.77, resulting in a year-to-date gain of 33%.
Buoyed by this positive performance, Stantec has revised its revenue growth outlook for the full year. The company now anticipates a growth range of 12% to 14%, surpassing its previous forecast of 10% to 13% growth. Additionally, Stantec has adjusted its earnings per share expectations, projected to rise by 22% to 25%, taking into account the revaluation of its long-term incentive plan. This marks an improvement from the initial estimate of 12% to 15% growth.
Notably, net income for the third quarter skyrocketed to 103.9 million Canadian dollars ($75.3 million), or C$0.94 per share, up from C$68 million, or C$0.61 per share, during the same period in the previous year.
Considering adjusted figures, the earnings per share surged to C$1.14, significantly outperforming the consensus forecast of C$0.97 from analysts surveyed by FactSet.
Moreover, revenue for the quarter reached C$1.32 billion, a remarkable increase of 14% compared to the expected C$1.27 billion.
This exceptional financial performance indicates Stantec's strong position in the market and bodes well for the company's future growth prospects.
Our Latest News
Visa Inc. Exceeds Earnings and Revenue Expectations in Q3
Visa Inc. outperforms expectations in Q3 with $4.2 billion net income and $8.12 billion total revenue. Significant growth in payment volume and cross-border tra...
Ionis Pharmaceuticals' Drug Candidate Shows Promise in Rare Genetic Disorder
Ionis Pharmaceuticals' olezarsen drug candidate achieves key goals in Phase 3 study for familial chylomicronemia syndrome, with significant triglyceride reducti...
JPMorgan Chase Expands Private Bank with Key Advisor Team
JPMorgan Chase's private bank adds a top advisor team from Citi Private Bank, bringing expertise to serve ultrahigh-net-worth clients. Globally, the private ban...